National trends in management of adult myxopapillary ependymomas.

National trends in management of adult myxopapillary ependymomas.
复制标题

DOI:
10.1016/j.jocn.2019.12.049
复制
发表时间:
2020-03
期刊:
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
影响因子:
--
通讯作者:
McClelland S 3rd
McClelland S 3rd
中科院分区:
其他
文献类型:
--
作者:
Scarpelli DB;Turina CB;Kelly PD;Khudanyan A;Jaboin JJ;McClelland S 3rd

文献摘要

参考文献

被引文献

相似文献

Myxopapillary ependymomas (MPE) are WHO Grade I ependymomas that annually occur in 0.05–0.08 per 100,000 people. Surgical resection is the recommended first line therapy. Due to the rarity of the disease, there is a relatively poor understanding of the use of radiotherapy (RT) in managing this disease. The National Cancer Database (NCDB) was analyzed for patterns of care for adult MPE diagnosed between 2002 and 2016. Of 753 qualifying cases, the majority of patients underwent resection (n = 617, 81.9%). A relatively small portion received RT (n = 103, 13.3%) with most receiving RT post-operatively (n = 98, 95.1%). The likelihood of patients to undergo resection and RT was associated with patient age at diagnosis (p = 0.002), tumor size (p < 0.001), and race (p = 0.017). Chemotherapy was not widely utilized (0.27% of patients). One limitation of our analysis is that there was no data on progression free survival (PFS), an important outcome given the high survival rate in this disease. Surgery remains the primary means to manage adult MPE. For spinal MPE, it is understood that gross total resection (GTR) should be attempted whenever possible as GTR has been associated with improved PFS in several studies. The impact of RT on overall survival (OS) is indeterminate given the 1.6% death rate in the cohort. Analyses of the impact of RT on PFS in a larger database would be beneficial for determining an algorithm for post-operative and definitive RT in this disease entity.
DOI: 10.1186/1477-5751-10-7
发表时间: 2011-05-31
期刊: Journal of negative results in biomedicine
影响因子: --
作者:
Ellison DW;Kocak M;Figarella-Branger D;Felice G;Catherine G;Pietsch T;Frappaz D;Massimino M;Grill J;Boyett JM;Grundy RG
通讯作者: Grundy RG
DOI: 10.1007/s11060-016-2167-0
发表时间: 2016-09-01
影响因子: 3.9
作者:
Bates, James E.;Choi, Gyujae;Milano, Michael T.
通讯作者: Milano, Michael T.
DOI: 10.1016/j.jocn.2012.12.010
发表时间: 2013-10
影响因子: 2
作者:
Oh, Michael C.;Tarapore, Phiroz E.;Kim, Joseph M.;Sun, Matthew Z.;Safaee, Michael;Kaur, Gurvinder;Aranda, Derick M.;Parsa, Andrew T.
通讯作者: Parsa, Andrew T.
DOI: 10.1002/pbc.27697
发表时间: 2019-06-01
影响因子: 3.2
作者:
Ager, Bryan J.;Christensen, Michael T.;Poppe, Matthew M.
通讯作者: Poppe, Matthew M.
DOI: 10.1215/s1152851704001231
发表时间: 2005-07-01
期刊: NEURO-ONCOLOGY
影响因子: 15.9
作者:
Gomez, DR;Missett, BT;Haas-Kogan, DA
通讯作者: Haas-Kogan, DA